• Abstract
• Full-Text PDF [607 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Waye, M
• Sing, C
• [+] on Google Scholar
• Waye, M
• Sing, C
• [+] on PubMed
• Waye, M
• Sing, C

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceuticals 2010, 3(10), 3343-3354; doi:10.3390/ph3103343

Review

Anti-Viral Drugs for Human Adenoviruses

Mary Miu Yee Waye*  and Chor Wing Sing

School of Biomedical Sciences, Croucher Laboratory for Human Genomics, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong

* Author to whom correspondence should be addressed.

Received: 2 September 2010; in revised form: 23 October 2010 / Accepted: 25 October 2010 / Published: 25 October 2010

(This article belongs to the Special Issue Antivirals)

Download PDF Full-Text [607 KB, uploaded 25 October 2010 14:53 CEST]

Abstract: There are many stages in the development of a new drug for viral infection and such processes are even further complicated for adenovirus by the fact that there are at least 51 serotypes, forming six distinct groups (A–F), with different degree of infectivity. This review attempts to address the importance of developing pharmaceuticals for adenovirus and also review recent development in drug discovery for adenovirus, including newer strategies such as microRNA approaches. Different drug screening strategies will also be discussed.

Keywords: adenovirus; pharmaceuticals; microRNA

Article Statistics

Cite This Article